OPTIC-III Prospective Non-Interventional Study To Optimize Photodynamic TUR-B In Clinical Practice
Phase of Trial: Clinical Phase Unknown
Latest Information Update: 17 Aug 2019
Price : $35 *
At a glance
- Drugs Hexyl aminolevulinate (Primary)
- Indications Bladder cancer
- Focus Diagnostic use
- Acronyms OPTIC-III
- Sponsors Ipsen
- 03 Nov 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 29 Apr 2014 According to the ClinicalTrials.gov record, status changed from recruiting to active, no longer recruiting.
- 23 Dec 2013 New trial record